The impact of CARA mandates on nurse practitioner controlled substance prescribing in Oregon: a cohort study.
Buprenorphine
Nurse practitioner
Opioids
Substance use disorder
Journal
Substance abuse treatment, prevention, and policy
ISSN: 1747-597X
Titre abrégé: Subst Abuse Treat Prev Policy
Pays: England
ID NLM: 101258060
Informations de publication
Date de publication:
31 01 2022
31 01 2022
Historique:
accepted:
31
12
2021
entrez:
1
2
2022
pubmed:
2
2
2022
medline:
3
5
2022
Statut:
epublish
Résumé
In 2017, the United States Comprehensive Addiction and Recovery Act (CARA) expanded authorization to prescribe buprenorphine for opioid use disorder (OUD) to nurse practitioners (NPs). Compared to physicians, NPs were required to complete 16 additional hours of training on controlled substance prescribing before a buprenorphine waiver application. As this differential additional education mandate was seen as a potential barrier, we evaluated the impact of this requirement on both NP waiver acquisition and prescribing of controlled substances, comparing NPs who obtained waivers to those who had not. Through 2016-2018 Oregon Prescription Drug Monitoring Program and linked NP licensure data, we identified factors associated with waiver acquisition at baseline (2016) and evaluated changes in controlled substance prescribing before (2016) and after waiver acquisition (2018). Using chi-square and Mann-Whitney U testing, we calculated and described controlled substance prescribing types, rates, and patient level quantities including co-prescribing of benzodiazepines and opioids by NPs. Multivariable linear regression compared prescribing by waivered and non-waivered NPs for significant changes in non-buprenorphine controlled substance prescribing. Waivered NPs were more likely to have a psychiatric certification, have prior disciplinary action, and have generally higher levels of non-buprenorphine controlled substance prescribing than their non-waivered counterparts. While there was a significant increase in opioid prescriptions per patient among waivered NPs, following CARA implementation, co-prescribing of benzodiazepines and opioids significantly declined among waivered NPs relative to non-waivered NPs. Although educational requirements were rescinded in 2021 for most applicants, enhanced opioid prescribing training should be incorporated into professional educational offerings regardless of regulatory mandate. We recommended continued focus on education regarding avoidance of high risk prescribing such as co-prescribing of opioids and benzodiazepines. NPs who acquire waivers may take on higher risk patients already using opioids, and these findings may represent transitions in practice and patient setting.
Sections du résumé
BACKGROUND
In 2017, the United States Comprehensive Addiction and Recovery Act (CARA) expanded authorization to prescribe buprenorphine for opioid use disorder (OUD) to nurse practitioners (NPs). Compared to physicians, NPs were required to complete 16 additional hours of training on controlled substance prescribing before a buprenorphine waiver application. As this differential additional education mandate was seen as a potential barrier, we evaluated the impact of this requirement on both NP waiver acquisition and prescribing of controlled substances, comparing NPs who obtained waivers to those who had not.
METHODS
Through 2016-2018 Oregon Prescription Drug Monitoring Program and linked NP licensure data, we identified factors associated with waiver acquisition at baseline (2016) and evaluated changes in controlled substance prescribing before (2016) and after waiver acquisition (2018). Using chi-square and Mann-Whitney U testing, we calculated and described controlled substance prescribing types, rates, and patient level quantities including co-prescribing of benzodiazepines and opioids by NPs. Multivariable linear regression compared prescribing by waivered and non-waivered NPs for significant changes in non-buprenorphine controlled substance prescribing.
RESULTS
Waivered NPs were more likely to have a psychiatric certification, have prior disciplinary action, and have generally higher levels of non-buprenorphine controlled substance prescribing than their non-waivered counterparts. While there was a significant increase in opioid prescriptions per patient among waivered NPs, following CARA implementation, co-prescribing of benzodiazepines and opioids significantly declined among waivered NPs relative to non-waivered NPs.
CONCLUSIONS
Although educational requirements were rescinded in 2021 for most applicants, enhanced opioid prescribing training should be incorporated into professional educational offerings regardless of regulatory mandate. We recommended continued focus on education regarding avoidance of high risk prescribing such as co-prescribing of opioids and benzodiazepines. NPs who acquire waivers may take on higher risk patients already using opioids, and these findings may represent transitions in practice and patient setting.
Identifiants
pubmed: 35101077
doi: 10.1186/s13011-022-00431-z
pii: 10.1186/s13011-022-00431-z
pmc: PMC8805433
doi:
Substances chimiques
Analgesics, Opioid
0
Controlled Substances
0
Benzodiazepines
12794-10-4
Buprenorphine
40D3SCR4GZ
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5Informations de copyright
© 2022. The Author(s).
Références
Online J Issues Nurs. 2007 Apr 02;12(2):7
pubmed: 21848354
JAMA. 2019 Apr 9;321(14):1407-1408
pubmed: 30964519
J Rural Health. 2020 Mar;36(2):187-195
pubmed: 31650634
J Gen Intern Med. 2016 Sep;31(9):1027-34
pubmed: 27177914
J Rural Health. 2022 Jan;38(1):112-119
pubmed: 33188544
Drug Alcohol Depend. 2020 May 25;213:108083
pubmed: 32505044
JAMA. 2021 Mar 23;325(12):1147-1148
pubmed: 33630020
Psychiatr Serv. 2008 Aug;59(8):909-16
pubmed: 18678689
Acad Med. 2020 Mar;95(3):470-480
pubmed: 31651435
J Rural Health. 2019 Jan;35(1):108-112
pubmed: 29923637
Drug Alcohol Depend. 2021 Jul 1;224:108729
pubmed: 33932744
JAMA Psychiatry. 2019 Mar 1;76(3):229-230
pubmed: 30586140
Subst Use Misuse. 2020;55(12):2035-2042
pubmed: 32646278
Clin J Pain. 2008 Jul-Aug;24(6):521-7
pubmed: 18574361